Anti-tumor effect of luteolin is accompanied by AMP-activated protein kinase and nuclear factor-κB modulation in HepG2 hepatocarcinoma cells

International Journal of Molecular Medicine

Volumn 28, Issue 1, 2011, Pages 25-31

  Hwang, Jin Taek ^a   Park, Ock Jin ^b   Lee, Yun Kyung ^b   Sung, Mi Jeong ^a   Hur, Haeng Jeon ^a   Kim, Myung Sunny ^a   Ha, Joo Hun ^c   Kwon, Dae Young ^a  

^a Korea Food Research Institute   (South Korea)

^b Hannam University Daedeok Valley Campus ^*  (South Korea)

^c Kyung Hee University Hospital   (South Korea)

Author keywords

AMP activated protein kinase; Hepatocarcinoma cells; Luteolin; Nuclear factor B; Reactive oxygen species

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUTEOLIN; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; LUTEOLIN; MICE; NEOPLASMS; NF-KAPPA B; PYRAZOLES; PYRIMIDINES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955838953     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.667     Document Type: Article

References (37)

1. Hughes TE: Emerging therapies for metabolic diseases - the focus is on diabetes and obesity. Curr Opin Chem Biol 13: 332-337, 2009.
2. Crozier A, Jaganath IB and Clifford MN: Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 26: 1001-1043, 2009.
3. Morisco F, Vitaglione P, Amoruso D, Russo B, Fogliano V and Caporaso N: Foods and liver health. Mol Aspects Med 29: 144-150, 2008. (Pubitemid 351312215)
4. Huntley AL: The health benefits of berry flavonoids for menopausal women: cardiovascular disease, cancer and cognition. Maturitas 63: 297-301, 2009.
5. http://en.wikipedia.org/wiki/Luteolin
6. Xavier CP, Lima CF, Preto A, Seruca R, Fernandes-Ferreira M and Pereira-Wilson C: Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Lett 281: 162-170, 2009.
7. Jang S, Kelley KW and Johnson RW: Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci USA 105: 7534-7539, 2008. (Pubitemid 351830053)
8. Lee CH, Jeon YT, Kim SH and Song YS: NF-kappaB as a potential molecular target for cancer therapy. Biofactors 29: 19-35, 2007. (Pubitemid 46985299)
9. Sethi G, Sung B and Aggarwal BB: Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med 233: 21-31, 2008.
10. Dobrovolskaia MA and Kozlov SV: Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership. Curr Cancer Drug Targets 5: 325-344, 2005. (Pubitemid 41097757)
11. Kabe Y, Ando K, Hirao S, Yoshida M and Handa H: Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 7: 395-403, 2005. (Pubitemid 40279807)
12. Ahn KS and Aggarwal BB: Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann NY Acad Sci 1056: 218-233, 2005. (Pubitemid 43030980)
13. Steinberg GR and Kemp BE: AMPK in health and disease. Physiol Rev 89: 1025-1078, 2009.
14. Hardie DG: AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785, 2007.
15. Huang CH, Tsai SJ, Wang YJ, Pan MH, Kao JY and Way D: EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53-positive and -negative human hepatoma cells. Mol Nutr Food Res 53: 1156-1165, 2009.
16. Hwang JT, Ha J and Park OJ: Combination of 5-fluorouracil and 16. genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun 332: 433-440, 2005. (Pubitemid 40731495)
17. Guo D, Hildebrandt IJ, Prins RM, et al: The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA 106: 12932-12937, 2009.
18. Kim HS, Hwang JT, Yun H, et al: Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53. J Biol Chem 283: 3731-3742, 2008.
19. Sung MJ, Kim DH, Jung YJ, et al: Genistein protects the kidney from cisplatin-induced injury. Kidney Int 74: 1538-1547, 2008.
20. Hwang JT, Kwak DW, Lin SK, Kim HM, Kim YM and Park OJ: Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Ann NY Acad Sci 1095: 441-448, 2007.
21. Jung JH, Lee JO, Kim JH, et al: Quercetin suppresses HeLa cell viability via AMPK-induced HSP70 and EGFR down-regulation. J Cell Physiol 223: 408-414, 2010.
22. Wang S, Liu Z, Wang L and Zhang X: NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 6: 327-334, 2009.
23. Cortes Sempere M, Rodriguez Fanjul V, Sanchez Perez I and Perona R: The role of the NFkappaB signalling pathway in cancer. Clin Transl Oncol 10: 143-147, 2008.
24. Lamberts RR, Onderwater G, Hamdani N, et al: Reactive oxygen species-induced stimulation of 5′AMP-activated protein kinase mediates sevoflurane-induced cardioprotection. Circulation 120: S10-S15, 2009.
25. Tucker G and Robards K: Bioactivity and structure of biophenols as mediators of chronic diseases. Crit Rev Food Sci Nutr 48: 929-966, 2008.
26. Larkin T, Price WE and Astheimer L: The key importance of soy isoflavone bioavailability to understanding health benefits. Crit Rev Food Sci Nutr 48: 538-552, 2008. (Pubitemid 351883144)
27. Shenouda NS, Zhou C, Browning JD, Ansell PJ, Sakla MS, Lubahn DB and Macdonald RS: Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer 49: 200-208, 2004. (Pubitemid 39487880)
28. Gerhauser C, Klimo K, Heiss E, et al: Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat Res 523-524: 163-172, 2003. (Pubitemid 36293243)
29. Horinaka M, Yoshida T, Shiraishi T, et al: Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 24: 7180-7189, 2005. (Pubitemid 41679280)
30. Murtaza I, Adhami VM, Hafeez BB, Saleem M and Mukhtar H: Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB. Int J Cancer 125: 2465-2473, 2009.
31. Deeb D, Gao X, Jiang H, et al: Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism. Biochem Pharmacol 79: 350-360, 2010.
32. Madan E, Prasad S, Roy P, George J and Shukla Y: Regulation of apoptosis by resveratrol through JAK/STAT and mitochondria- mediated pathway in human epidermoid carcinoma A431 cells. Biochem Biophys Res Commun 377: 1232-1237, 2008.
33. Roy P, Madan E, Kalra N, et al: Resveratrol enhances ultraviolet B-induced cell death through nuclear factor-kappaB pathway in human epidermoid carcinoma A431 cells. Biochem Biophys Res Commun 384: 215-220, 2009.
34. Thomson DM, Fick CA and Gordon SE: AMPK activation attenuates S6K1, 4E-BP1, and eEF2 signaling responses to high-frequency electrically stimulated skeletal muscle contractions. J Appl Physiol 104: 625-632, 2008. (Pubitemid 351468789)
35. Horman S, Browne G, Krause U, et al: Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12: 1419-1423, 2002. (Pubitemid 34915545)
36. Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S and Levine AJ: The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 67: 3043-3053, 2007. (Pubitemid 46724841)
37. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, Deepinho RA and Cantley LC: The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99, 2004. (Pubitemid 38903165)